• Price (EUR)1.31
  • Today's Change0.02 / 1.55%
  • Shares traded0.00
  • 1 Year change-45.07%
  • Beta--
Data delayed at least 15 minutes, as of May 30 2023 07:13 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Key statistics

On Tuesday, Everest Medicines Ltd (6HN:FRA) closed at 1.31, 71.02% above the 52 week low of 0.766 set on Oct 31, 2022.
52-week range
0.766Oct 31 20223.15Jan 26 2023
Short selling activity
Provided by S&P Global Market Intelligence
Previous close1.29
Average volume15.91
Shares outstanding315.55m
Free float308.11m
P/E (TTM)--
Market cap3.57bn HKD
EPS (TTM)-0.9474
Data delayed at least 15 minutes, as of May 30 2023 07:13 BST.
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
S&P Global Market Intelligence Short Selling Activity © S&P Global Market Intelligence. All rights reserved.
Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.